MAPK3 and lung carcinoma: As reported, fisetin could inhibit the proliferation and migration of human laryngeal cancer via ERK1/2 and AKT/NF-KB/mTOR signaling pathways and induce apoptosis in human lung cancer through the MAPK signaling pathway [15, 16].